Insider Trading Alert - ACET, WWD And AMSG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 4, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $203.25 to $160,379,000.00.

Highlighted Stocks Traded by Insiders:

Aceto (ACET) - FREE Research Report

Debenedittis Frank, who is Sr. Vice President at Aceto, sold 4,000 shares at $24.41 on June 4, 2015. Following this transaction, the Sr. Vice President owned 72,703 shares meaning that the stake was reduced by 5.21% with the 4,000-share transaction.

The shares most recently traded at $24.52, up $0.11, or 0.46% since the insider transaction. Historical insider transactions for Aceto go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 9,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 24,164

The average volume for Aceto has been 115,200 shares per day over the past 30 days. Aceto has a market cap of $714.8 million and is part of the basic materials sector and chemicals industry. Shares are up 13.59% year-to-date as of the close of trading on Thursday.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The stock currently has a dividend yield of 0.98%. The company has a P/E ratio of 27.9. Currently, there are no analysts who rate Aceto a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACET - FREE

TheStreet Quant Ratings rates Aceto as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Aceto Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Woodward (WWD) - FREE Research Report

Donovan Paul, who is Director at Woodward, bought 72 shares at $51.99 on June 4, 2015. Following this transaction, the Director owned 35,877 shares meaning that the stake was boosted by 0.2% with the 72-share transaction.

The shares most recently traded at $53.35, up $1.36, or 2.55% since the insider transaction. Historical insider transactions for Woodward go as follows:

  • 4-Week # shares bought: 2,378
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 2,378
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 2,378
  • 24-Week # shares sold: 7,000

The average volume for Woodward has been 296,600 shares per day over the past 30 days. Woodward has a market cap of $3.5 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 7.68% year-to-date as of the close of trading on Thursday.

Woodward, Inc. designs, manufactures, and services energy control and optimization solutions for the aerospace and energy markets worldwide. The stock currently has a dividend yield of 0.76%. The company has a P/E ratio of 19.1. Currently, there are 6 analysts who rate Woodward a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WWD - FREE

TheStreet Quant Ratings rates Woodward as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Woodward Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amsurg (AMSG) - FREE Research Report

Holden Christopher A, who is President and CEO at Amsurg, sold 3,000 shares at $69.02 on June 4, 2015. Following this transaction, the President and CEO owned 291,496 shares meaning that the stake was reduced by 1.02% with the 3,000-share transaction.

The shares most recently traded at $69.00, down $0.02, or 0.03% since the insider transaction. Historical insider transactions for Amsurg go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 18,098
  • 24-Week # shares sold: 27,097

The average volume for Amsurg has been 328,900 shares per day over the past 30 days. Amsurg has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are up 25.18% year-to-date as of the close of trading on Thursday.

AmSurg Corp., through its subsidiaries, provides ambulatory and physician services in the United States. The company operates through two divisions, Ambulatory Services and Physician Services. The company has a P/E ratio of 61.1. Currently, there are 8 analysts who rate Amsurg a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMSG - FREE

TheStreet Quant Ratings rates Amsurg as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, increase in net income and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Amsurg Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Aceto (ACET) Stock Tumbles on Q4 Miss

Aceto (ACET) Stock Tumbles on Q4 Miss

5 Hated Stocks You Should Love

5 Hated Stocks You Should Love

Insider Trading Alert - XPLR, ACET And OMCL Traded By Insiders

Insider Trading Alert - XPLR, ACET And OMCL Traded By Insiders

Insider Trading Alert - CMCSA, GBX And ACET Traded By Insiders

Insider Trading Alert - CMCSA, GBX And ACET Traded By Insiders

Insider Trading Alert - ASFI, ACET And HYGS Traded By Insiders

Insider Trading Alert - ASFI, ACET And HYGS Traded By Insiders